Astellas Backed By Full Pipeline To Battle Japan Price Controls and Slow Approvals In U.S.
This article was originally published in PharmAsia News
Executive Summary
Astellas' user fee date for immunosuppressant Prograf MR (tacrolimus) NDA pending at the U.S. FDA has been extended for another three months, the company told a third quarter earnings call Feb.1 at its headquarters in Tokyo
You may also be interested in...
Astellas’ Once-Daily Tacrolimus Again “Approvable” For Kidney Transplant Patients
Astellas Pharma received a second U.S. FDA "approvable" letter for use of its long-lasting immunosuppressant FK506 in kidney transplant patients, the company said March 14.
Astellas’ Once-Daily Tacrolimus Again “Approvable” For Kidney Transplant Patients
Astellas Pharma received a second U.S. FDA "approvable" letter for use of its long-lasting immunosuppressant FK506 in kidney transplant patients, the company said March 14.
EMEA Recommends Approval For Astellas’ Mycamine
PERTH, Australia - The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended that Astellas Pharma's antifungal Mycamine (micafungin) be approved for candidiasis, Astellas announced Feb. 21